Search Results - "Tutt, A.L."

  • Showing 1 - 6 results of 6
Refine Results
  1. 1

    Validation of an ELISA for the determination of rituximab pharmacokinetics in clinical trials subjects by Hampson, G., Ward, T.H., Cummings, J., Bayne, M., Tutt, A.L., Cragg, M.S., Dive, C., Illidge, T.M.

    Published in Journal of immunological methods (31-08-2010)
    “…Rituximab is a chimeric anti-CD20 monoclonal antibody that has revolutionised the treatment of many B-cell malignancies, and is now increasingly being used in…”
    Get full text
    Journal Article
  2. 2

    Development, validation and application of ELISAs for pharmacokinetic and HACA assessment of a chimeric anti-CD40 monoclonal antibody in human serum by Chowdhury, F., Tutt, A.L., Chan, C., Glennie, M., Johnson, P.W.

    Published in Journal of immunological methods (15-12-2010)
    “…As part of a Phase I chimeric anti-CD40 monoclonal antibody clinical trial, two enzyme-linked immunosorbent assays (ELISAs) were developed for secondary…”
    Get full text
    Journal Article
  3. 3

    Treatment of B-cell lymphomas with combination of bispecific antibodies and saporin by French, R R, Hamblin, T J, Bell, A J, Tutt, A L, Glennie, M J

    Published in The Lancet (British edition) (22-07-1995)
    “…We report the use of a bispecific F(ab')2 antibody to target the ribosome-inactivating protein saporin to the surface antigen CD22 in the treatment of…”
    Get more information
    Journal Article
  4. 4

    Response of B-cell lymphoma to a combination of bispecific antibodies and saporin by French, Ruth R., Bell, A.J., Hamblin, T.J., Tutt, A.L., Glennie, M.J.

    Published in Leukemia research (01-07-1996)
    “…Observations are described using a combination of two bispecific F(ab′) 2 antibodies (BsAb) to deliver the ribosome-inactivating protein, saporin, in the…”
    Get full text
    Journal Article
  5. 5

    Characterization of a new monoclonal anti-Fc gamma RII antibody, AT10, and its incorporation into a bispecific F(ab')2 derivative for recruitment of cytotoxic effectors by Greenman, J, Tutt, A L, George, A J, Pulford, K A, Stevenson, G T, Glennie, M J

    Published in Molecular immunology (01-11-1991)
    “…Fc gamma RII (CDw32) on monocytes is capable of triggering both phagocytosis and lysis of chick red blood cells (CRBC) coated with antibody of the appropriate…”
    Get more information
    Journal Article
  6. 6

    Monoclonal Anti-Light Chain Idiotype as a Tumor-Specific Probe for Human Neoplastic B Lymphocytes by Wrightham, M., Tutt, A.L., Glennie, M.J., Hamblin, T.J., Stevenson, G.T., Stevenson, F.K.

    Published in Blood (01-03-1987)
    “…Tumor cells from patients with B cell neoplasms often secrete small amounts of free monoclonal light chains that can be found in the urine. Such tumor-derived…”
    Get full text
    Journal Article